A comparison of several international clinical trials of beta-blocker drugs has shown there are notable differences in how well the drugs prevent deaths in heart failure patients, based on where the patients were treated. In this study, US patients apparently had a lower survival rate with beta-blocker treatment compared to patients outside the US.